| Patient | Alan Turing |
|---|---|
| Date of birth | 1912-06-23 |
| Identifiers | MRN HR-ML007-SYN-TD; SSN (made up) 000-07-6290 |
| Document date | 1953-10-06 |
| Author | Rupert Hallam, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-month review of gynecomastia and depression in continuation treatment. [S]
Mr. Turing returns about six months after his first visit. His right ankle sprain from August healed within three weeks and he is back to about 40 km a week. He has finished the course of 16 psychotherapy sessions and now sees the psychologist monthly. He feels like himself, sleeps about seven hours, and has been changing at his running club again for a month. He takes bupropion XL 150 mg and cholecalciferol every morning, has missed no doses, and has no side effects. The breast tissue is no longer tender, though he can still feel a small disc on the left. He has had no suicidal thoughts. [S]
| Element | Detail |
|---|---|
| Interval change | Feels like himself; back with his running club |
| Ankle | Sprain healed within three weeks |
| Psychotherapy | Course of 16 sessions finished; monthly sessions now |
| Breasts | No tenderness; small disc on the left |
| Safety | No suicidal thoughts |
| PHQ-9 | 4 |
| System | Result | Finding |
|---|---|---|
| Breast | Negative | No tenderness or discharge |
| Genitourinary | Negative | Libido and erections normal |
| Musculoskeletal | Negative | Ankle recovered |
| Psychiatric | Negative | Mood good; no suicidal thoughts, elevated mood, or racing thoughts |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1953-04-14 | active | S |
| Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning | Oral route | 1953-06-09 | active | S |
| Ibuprofen 400 mg oral tablet, one tablet by mouth up to three times a day with food for no more than 5 days | One tablet up to three times a day with food, for no more than 5 days | Oral route | 1953-08-25 to 1953-08-30 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1953-10-06 | Body height | 178 | cm | S |
| 1953-10-06 | Body weight | 68.6 | kg | S |
| 1953-10-06 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 1953-10-06 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1953-10-06 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1953-10-06 | Heart rate | 54 | /min | S |
| 1953-10-06 | Respiratory rate | 14 | /min | S |
| 1953-10-06 | Body temperature | 36.6 | Cel | S |
| 1953-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1953-10-06 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1953-10-06 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S | ||
| 1953-10-06 | Testosterone [Mass/volume] in Serum or Plasma | 536 | ng/dL | 264-916 ng/dL | Normal | S |
| 1953-10-06 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 24 | pg/mL | 7.6-42.6 pg/mL | Normal | S |
| 1953-10-06 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 | ng/mL | 30-100 ng/mL | Normal | S |
Vital signs recorded on 1953-10-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, lean, and cheerful |
| Breast | Examined with his agreement: a soft, non-tender disc of glandular tissue about 2 cm behind the left nipple and 1 cm behind the right; no discrete mass, skin change, discharge, or nodes |
| Mental status | Alert; mood "good"; affect full and reactive; thought process linear; no suicidal ideation; insight and judgment good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed | N62 | S — Synthetic modern diagnosis. That the hormone treatment caused breast growth is reported in the sources (D, mentioned once in his own words); the examination findings are synthetic. |
| Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | resolved | confirmed | E23.1 | S — Synthetic consequence of high-dose estrogen, which suppresses LH and FSH; recovery is expected once it stops. |
| Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed | T38.5X5A | S — Synthetic modern framing of the documented hormone treatment imposed after his conviction (D); in the modern episode it is recorded as iatrogenic harm. |
| Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed | F32.1 | S — Synthetic modern diagnosis. That he sought Jungian analysis after the trial is documented (D); calling his state then a depressive illness is a retrospective interpretation (R). |
| Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | resolved | confirmed | E55.9 | S — Synthetic finding of the bone-health workup. |
| Right lateral ankle sprain while trail running, able to bear weight, Ottawa ankle rules negative; resolved | active | confirmed | S93.401A | S — Synthetic sprain at an unscheduled visit, chosen to teach the Ottawa ankle rules and how to protect a depression plan that relies on running; it does not echo any documented injury. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Breast examination for size, tenderness, and any discrete mass | Every visit until the gynecomastia settles | Completed today | A soft, non-tender disc about 2 cm on the left and 1 cm on the right; no discrete mass |
| Laboratory | Testosterone and estradiol at six months | Once, to confirm sustained recovery | Completed today | Testosterone 536 ng/dL and estradiol 24 pg/mL, normal |
| Laboratory | 25-hydroxyvitamin D on replacement | About three to six months after starting | Completed today | 38 ng/mL, up from 22 |
| Referral | Surgical opinion for persistent gynecomastia | If it persists about twelve months and troubles him | Due | Not yet: six months since the estrogen stopped and still shrinking |
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 4: remission |
| Survey | Monthly PHQ-9 between the sixteen-week review and today | At least monthly during acute treatment | Deferred | Not done, a deviation from the protocol: no interim PHQ-9 was scheduled after the response at sixteen weeks, although remission had not been reached, leaving nine weeks unmeasured. No harm resulted judging by today's review: he reached remission and had no suicidal thoughts, and he saw the psychologist throughout. Corrective action: the clinic registry now books a monthly PHQ-9 call until a remission score is recorded |
| Survey | GAD-7 | With the PHQ-9 when anxiety symptoms were present at baseline | Completed today | 3 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior since the last visit; PHQ-9 item 9 scored 0. Protective factors stronger than at intake. Safety plan reviewed |
| Medication safety | Adherence, adverse effects, and blood pressure on bupropion | Every visit during active treatment | Completed today | No missed doses; no side effects; blood pressure 118/72 mmHg |
| Self-management | Psychotherapy, sleep, running, and social contact | Every visit during active treatment | Completed today | Course of 16 sessions finished, monthly now; sleep about seven hours; running 40 km a week with his club |
| Laboratory | Lithium, anticonvulsant, or antipsychotic monitoring (levels, metabolic tests, AIMS) | Only on those drugs | Not indicated | Not on any of these drugs |
Goal progress:
Guideline basis: EAA clinical practice guidelines: gynecomastia evaluation and management (2019); Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (2018); Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline (2012); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Preventive visit in two weeks; depression review with PHQ-9 in about two months. Next scheduled visit 1953-10-20: periodic adult preventive visit. [S]